218 related articles for article (PubMed ID: 30152527)
21. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.
Denney WS; Sonnenberg GE; Carvajal-Gonzalez S; Tuthill T; Jackson VM
Br J Clin Pharmacol; 2017 Feb; 83(2):326-338. PubMed ID: 27621150
[TBL] [Abstract][Full Text] [Related]
22. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
24. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
Seitz L; Jin L; Leleti M; Ashok D; Jeffrey J; Rieger A; Tiessen RG; Arold G; Tan JBL; Powers JP; Walters MJ; Karakunnel J
Invest New Drugs; 2019 Aug; 37(4):711-721. PubMed ID: 30569245
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
27. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers.
Hu Y; Zhang H; Li X; Mai J; Yang L; Yan J; Li Y; Sun J; Xu W; He S; Li J; Wu M
Expert Opin Investig Drugs; 2022 Sep; 31(9):977-985. PubMed ID: 34633260
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
30. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
31. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
32. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
Badman MK; Chen J; Desai S; Vaidya S; Neelakantham S; Zhang J; Gan L; Danis K; Laffitte B; Klickstein LB
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):395-410. PubMed ID: 31823525
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Boof ML; Géhin M; Voors-Pette C; Hsin CH; Sippel V; Strasser DS; Dingemanse J
Br J Clin Pharmacol; 2024 Feb; 90(2):588-599. PubMed ID: 37752659
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.
Patat A; Parks V; Raje S; Plotka A; Chassard D; Le Coz F
Br J Clin Pharmacol; 2009 Mar; 67(3):299-308. PubMed ID: 19523013
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.
Cutler DL; Tendolkar A; Grachev ID
J Clin Pharm Ther; 2012 Oct; 37(5):578-87. PubMed ID: 22676397
[TBL] [Abstract][Full Text] [Related]
36. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
37. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Frankel E; Song M; Li S; Jiang J; Thurmond RL; Randazzo B
J Drugs Dermatol; 2018 Aug; 17(8):873-879. PubMed ID: 30124726
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
40. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]